DEDavid Elliman

David Elliman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David Elliman has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Examining the whole-cell pertussis vaccine scare and its repercussions

    by David Ac Elliman, Helen E Bedford, Euan M Ross

    In 1974, a paper published in Archives described a series of children who suffered serious acute and, usually long-term, neurological events after inoculation with the combined diphtheria/tetanus/pertussis vaccine. Despite this being a case series, with no controls, the authors posited a causal connection and blamed the whole-cell pertussis component. This message was taken up by the UK media and raised in Parliament. Almost overnight the uptake of the combined vaccine fell and notifications of pertussis rose. It took 15 years for uptake of the vaccine to recover. Twenty-four years following publication of the Archives paper, a smaller case series was published in the Lancet , claiming a link between bowel problems and autism. A temporal association with the MMR vaccine was noted and the lead author called for a ban on the combined vaccine. This resulted in a fall in MMR vaccine uptake. There is now a significant body of evidence in favour of no causal link but many parents remain hesitant about vaccinating their children. Authors, editors and publishers should be aware of the effect that an article published in a high-quality academic publication can have on public health. Although it is not appropriate to suppress good research, whatever the message, it is an ethical imperative to ensure it is truly evidence-based.


  • Open Access

    Methods and mechanisms for measuring and monitoring outcomes from newborn bloodspot screening: a scoping review

    by Katie Scandrett, Jacqueline Dinnes, Breanna Morrison, April Coombe, Ridhi Agarwal, Isaac Adu Asare, Phoebe Mead, Andy De Souza, David Elliman, Silvia Lombardo, et al.

    Background: Newborn bloodspot screening offers the potential to detect rare diseases early, enabling timely treatment that can reduce mortality and morbidity. Generating evidence for rare diseases often depends on observational data, making it challenging to formulate recommendations for new screening programmes and evaluate the effectiveness of existing ones. Objective(s): To identify the range of methods and mechanisms used to measure and monitor outcomes from newborn screening programmes using a scoping review. Methods: We included studies published between 2019 and 2024, which evaluated a current or candidate newborn screening programme, or which reported outcomes in screen-detected cases. Studies were categorised into four groups: group 1 reported a comparison and follow-up; group 2 reported a comparison but no follow-up; group 3 reported no comparison with follow-up; and group 4 reported no comparison or follow-up. Data were extracted from a random sample of studies within each group; studies in group 1 were prioritised. Results were reported narratively according to study group. The review was conducted and reported according to current guidance for scoping reviews. Data sources: EMBASE (Ovid), MEDLINE (Ovid) and Science Citation Index (Web of Science – Clarivate). Results: We included 574 primary studies and extracted data from 178. Of the 75 studies in group 1, most compared screen-detected cases with controls (74%). Studies in this group used newborn bloodspot programme databases, registries or record review to identify participants and outcomes; only six (8%) reported use of record linkage. Studies in group 2 ( n = 31) mostly reported comparisons of screening tests (25, 81%). Over half of studies in group 3 ( n = 34) used newborn bloodspot programme databases to identify participants (53%) and outcomes (65%). A similar pattern was seen in the group 4 ( n = 38). Studies reporting follow-up typically relied on retrospective record review or were not well reported. Across all study groups, data on accuracy, epidemiology and genetic variants were common. Studies in group 1 also reported on the effectiveness of newborn bloodspot screening (32/75, 43%), treatment effectiveness (20%) or harms of newborn bloodspot screening (3%). Limitations: Restricting data extraction to a random sample of studies risks missing novel methods or mechanisms. Conclusions: Many studies reported test accuracy metrics and genetic variants in newborn screening. Some data on programme effectiveness were identified, but assessment of potential harms remains limited, and methods for follow-up were poorly reported. Assessment of harms, including overdiagnosis and psychological impact, is crucial to ensuring a net benefit at the population level. Future work: In a second phase of work, an in-depth assessment of studies using different methods and mechanisms will be conducted to identify the extent to which they can provide outcome data to inform the evaluation of ongoing and candidate screening programmes. Funding: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR167910.


  • Open Access

    Evaluating whole genome sequencing for rare diseases in newborn screening: evidence synthesis from a series of systematic reviews

    by Karoline Freeman, Jacqueline Dinnes, Bethany Shinkins, Corinna Clark, Inès Kander, Katie Scandrett, Shivashri Chockalingam, Aziza Osman, Naila Dracup, Rachel Court, et al.

    Background: Newborn screening using whole genome sequencing is being evaluated in numerous projects across the world, including Genomics England Limited’s Generation Study. It presents considerable challenges for policy advisors, not least, given the logistics of simultaneously evaluating the evidence for the suggested 200 rare genetic conditions. The ‘genotype-first’ approach has the potential for harms through overdiagnosis, and benefits are uncertain. Objective: To assess different approaches to evaluating whole genome sequencing for newborn screening to inform the development of a robust method of evaluation for informing policy decisions. Methods: We approached the objective with systematic review methods for a sample of five conditions (considering gene penetrance, expressivity, accuracy and effectiveness of whole genome sequencing and effect of earlier treatment) (search inception to November 2023), evaluated the National Institutes of Health [US] Clinical Genome Resource (ClinGen) as an alternative evidence source for the five conditions and we compared this to a review of genomic studies of newborn screening cohorts reporting penetrance for pathogenic variants of any paediatric condition (search inception to February 2024). We undertook a methodological review of economic evaluations of whole genome sequencing/whole exome sequencing (search inception to January 2024) and explored public views on evaluating whole genome sequencing. Data sources: MEDLINE (Ovid), EMBASE (Ovid), Web of Science, Science Citation Index (via Clarivate), the Cochrane Library (via Wiley), cost-effectiveness analysis registry and American Economic Association electronic bibliography. Actionability reports and scores from the Clinical Genome Resource website (downloaded 30 April 2024). Results: The traditional review approach identified 268 studies reporting the genetic spectrum of individuals with the five conditions or benefits of earlier, symptomatic treatment. No evidence on the penetrance and expressivity or the accuracy or effectiveness of whole genome sequencing in newborns was identified. A review of 200 conditions would take a team of five reviewers 23 years to complete. Clinical Genome Resource reviews were available for four or five conditions. All four ‘actionability’ ratings disagreed with the findings of our reviews. Our review of 14 genomic studies of newborn screening cohorts found insufficient information to allow individual highly penetrant pathogenic variants for any condition to be identified. None of the 86 economic evaluations of whole genome sequencing or whole exome sequencing were set in a screening context. Some micro-costing studies are available that could help understand the resource use and costs associated with whole genome sequencing. Following a series of patient and public involvement meetings, attendees appreciated the uncertainties of whole genome sequencing. A wider stakeholder perspective is needed to inform policy decisions. Limitations: Although we only examined five conditions in depth, the consistency in lack of data suggests that our conclusions are robust. Conclusions: The systematic review approach for evaluating whole genome sequencing of newborns identified a paucity of high-quality evidence. Extending the review to all 200 conditions is not feasible. Currently, the use of existing genome resources and review of genomic studies of newborn screening cohorts are not viable alternatives. The cost-effectiveness of whole genome sequencing in a newborn screening context is unknown. Future work: Large-scale collaborative research is required to evaluate the short- and long-term harms, benefits and economic implications of whole genome sequencing for screening newborns. We propose a staged approach to evaluation, considering only conditions with pathogenic variants with high penetrance to minimise harm from overdiagnosis. Study registration: This study is registered as PROSPERO CRD42023475529. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis Programme (NIHR award ref: NIHR159928) and is published in full in Health Technology Assessment ; Vol. 29, No. 65. See the NIHR Funding and Awards website for further award information.


  • Open Access

    Challenges in evaluating whole genome sequencing for newborn screening: series of systematic reviews and roadmap for evidence generation for policy advisers

    by Karoline Freeman, Dylan Taylor, Jacqueline Dinnes, Corinna C A Clark, Inès Kander, Katie Scandrett, Shivashri Chockalingam, Naila Dracup, Rachel Court, Furqan Butt, et al.

    Objective: To evaluate systematic review approaches to synthesising evidence for policy advisers who are considering whether to screen newborns for hundreds of rare diseases using whole genome sequencing. Design: Series of systematic reviews and roadmap for evidence generation for policy advisers. Data sources: Medline, Embase, Science Citation Index, Cochrane Library. Methods: 200 conditions included in Genomics England's Generation Study were stratified into five groups and one condition randomly selected from each group using criteria designed to maximise variability and availability of data. 30 systematic reviews were undertaken (five conditions, six review questions) about penetrance, detection rate, accuracy, benefit of earlier treatment, and benefits and harms of screening for the five conditions (search from inception to November 2023). Results were synthesised and reviewer time recorded. Genomic studies of newborn screening cohorts that reported penetrance were systematically reviewed using a non-condition specific approach (search inception to January 2024). The conditions and genes selected for reporting by these studies were identified. ClinGen was explored for synthesising evidence. All approaches were assessed by considering review effort and level and quality of evidence. Results: The five conditions selected for systematic review were pyridoxine dependent epilepsy, heritable retinoblastoma, X linked hypophosphataemic rickets, familial haemophagocytic lymphohistiocytosis, and medium chain acyl-CoA dehydrogenase deficiency. 19 689 titles were screened and 268 papers included that addressed two of six research questions (detection rate and treatment benefit). No studies were identified for the remaining four research questions. Total reviewer time for five conditions was seven months. A team of five reviewers would take over 20 years to conduct similar reviews for 200 conditions. 10 published genomic studies of newborn screening cohorts were identified with a total of 76 268 newborns. The number of conditions screened for varied from 74 to 903, with low concordance (two of 1453 genes were included in all 10 studies). Selection of conditions was primarily based on clinical opinion. All studies reported and acted on genetic findings considered clinically significant, preventing collection of penetrance data. Conclusions: Current evidence synthesis methods are neither feasible nor fruitful to provide policy advisers like the UK National Screening Committee with the evidence needed to understand the benefits and harms of newborn screening for multiple conditions using whole genome sequencing because the evidence is not available to synthesise. Evidence should be created through studies that only report pathogenic variants to parents and clinicians where penetrance and expressivity have been established through empirical evidence rather than clinical opinion. A roadmap for future evidence generation is proposed to highlight the need for new evidence generation combined with a staged approach to evaluation, focusing on pathogenic variants with evidence of high penetrance and expressivity. Registration: Review registration PROSPERO (CRD42023475529).